Is Zymeworks Inc. (ZYME) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.0% / 30% | 12.3% / 30% | 3.0% / 30% | 26.13% / 5% | ✗ NOT HALAL |
| DJIM | 1.0% / 33% | 12.3% / 33% | 3.0% / 33% | 26.13% / 5% | ✗ NOT HALAL |
| MSCI | 4.0% / 33% | 48.8% / 33% | 12.1% / 33% | 26.13% / 5% | ✗ NOT HALAL |
| S&P | 1.0% / 33% | 12.3% / 33% | 3.0% / 33% | 26.13% / 5% | ✗ NOT HALAL |
| FTSE | 4.0% / 33% | 48.8% / 33% | 12.1% / 50% | 26.13% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -29.3% | |
| Operating Margin | -1755.5% | |
| Net Margin | -76.6% | |
| Return on Equity (ROE) | -26.7% | |
| Return on Assets (ROA) | -14.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$33M |
| Free Cash Flow | -$35M |
| Total Debt | $18M |
| Debt-to-Equity | 6.8 |
| Current Ratio | 5.9 |
| Total Assets | $347M |
Price & Trading
| Last Close | $24.69 |
| 50-Day MA | $23.50 |
| 200-Day MA | $19.35 |
| Avg Volume | 760K |
| Beta | 1.3 |
|
52-Week Range
$9.03
| |
About Zymeworks Inc. (ZYME)
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Zymeworks Inc. (ZYME) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Zymeworks Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Zymeworks Inc.'s debt ratio?
Zymeworks Inc.'s debt ratio is 1.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 4.0%.
What are Zymeworks Inc.'s key financial metrics?
Zymeworks Inc. has a market capitalization of $1.8B, and revenue of $106M. The company maintains a gross margin of -29.3% and a net margin of -76.6%. Return on equity stands at -26.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.